Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: new + [flash] + solagran  Related to the article below (Last Update: 8/5/2008)

Search goes on for hidden value
The Australian, Australia - Jul 7, 2008
Avoiding Solagran, the Opes Prime-ravaged Russian drug developer, was a no-brainer. And with three takeover offers for Beyond International evaporating, ...
Source: Google News

A new flash-erase EEPROM cell with a sidewall select-gate on itssource side
K Naruke, S Yamada, E Obi, S Taguchi, M Wada - Electron Devices Meeting, 1989. Technical Digest., …, 1989 - ieeexplore.ieee.org
Page 1 CH2637-7(89/0000-0603 $1.00 ? 1989 IEEE IEDM 89-603 A NEW FLASH-ERASE EEPROM
CELL WITH A SIDEWALL SELECF-GATE ON ITS SOURCE SIDE K.Naruke, S.Yamada, E ...

A new flash E 2 PROM cell using triple polysilicon technology
F Masuoka, M Asano, H Iwahashi, T Komuro, S Tanaka - 1984 International Electron Devices Meeting, 1984 - ieeexplore.ieee.org
Page 1. A NEW FLASH EPROM CELL USING TRIPLE POLYSILICON TECHNOLOGY FUJI0 MASUOKA,
MASAMICHI ASANO, HIROSHI IWAHASHI, TEISUKE KOMURO and SHINICHI TANAKA ...

A new flash method for measuring the toxicity of solid and colored samples -
J Lannalainen, R Juvonen, K Vaajasaari, M Karp - Chemosphere, 1999 - Elsevier
... A NEW FLASH METHOD FOR MEASURING THE TOXICITY OF SOLID AND COLORED SAMPLES ? 1 ?
.2 Juha Lappalainen 1"3 , RIsto Juvonen, Kati Vaajasaarl, Matti Karp 3 ...

A new flash memory management for flash storage system -
HJ Kim, SG Lee - Computer Software and Applications Conference, 1999. COMPSAC …, 1999 - ieeexplore.ieee.org
Page 1. A New Flash Memory Management for Flash Storage System Han-joon Kim
Sang-goo Lee Department of Computer Science Seoul National ...

A new flash mixing -
IJ Sackmann - The Astrophysical Journal, 1980 - adsabs.harvard.edu
Title: A new flash mixing. Authors: Sackmann, IJ. ... m. PG SAGITTAE The above new flash
mixing may provide the missing clue for FG Sge's mixing behavior. ...

[CITATION] New flash enhancements up ante
A Cataldo - … and AT29BV020, and Samsung Semiconductor's KM29V32000* flash …

90-nm-node multi-level AG-AND type flash memory with cell size of true 2 F/sup 2//bit and …
Y Sasago, H Kurata, T Arigane, K Otsuga, T … - Electron Devices Meeting, 2003. IEDM'03 Technical Digest. …, 2003 - ieeexplore.ieee.org
... Source-side injection pro- grarnming is applicable to the new flash cell;
therefore, the cell programming time is reduced to 1 tis. ...

Design and performance of a new flash EEPROM on SOI (SIMOX) substrates
A Zaleski, DE Ioannou, D Flandre, JP Colinge - SOI Conference, 1994 Proceedings., 1994 IEEE International, 1994 - ieeexplore.ieee.org
... DESIGN AND PERFORMANCE OF A NEW FLASH EEPROM ON SOI(SIM0X) SUBSTRATES ... A new Flash
EEPROM cell and a novel erasing scheme on SO1 substrates are reported. This ...

[CITATION] A New Flash Memory Management for Flash Storage System
K Han-Joon, L Sang-goo - Proceedings of the Computer Software and Applications …, 1999

Method and apparatus for protecting flash memory -
PE Mattison - US Patent 6,363,463, 2002 - freepatentsonline.com
... The system of claim 18, where the flash memory upgrade program includes a digital
signature being a hash value of at least the new flash memory image encrypted ...

Source: Google Scholar

Treating Chronic Liver Diseases - Australia's Solagran Registers New Pharmaceutical In Russia
Australian Biotech Solagran Limited (ASX: SLA) announced that it had received formal documentation from the Russian Ministry of Heath advising that pharmaceutical registration of both its substance Bioeffective® R and the associated medicine Ropren has been finalised. Ropren is a safe and effective natural hepatoprotector which will be used to treat chronic liver disease, including hepatitis and cirrhosis.

Solagran will now focus on scaling up production facilities sufficient to meet the expected demand in Russia. It can also now initiate the next stage of its Ropren strategy which is to obtain pharmaceutical registration in the European Union as a precursor to taking it to North America and Asia.
Ropren is a unique natural medicine. Its active ingredient Bioeffective® R is one of a family of 17 Bioeffectives® that Solagran's research team has developed over ! 30 years. Each has multifaceted activity and few if any side e! ffects.
Ropren has been approved in Russia as a strong and effective natural hepatoprotector. Clinical trials have also demonstrated that Ropren has the potential to normalise lipid metabolism, strengthen the immune system, prevent and treat neurodegenerative disorders, and deal with conditions associated with drug and alcohol addiction.

The ability of Ropren to deal so effectively with chronic liver disease will have a very positive social impact in Russia. There are more than 10 million people with liver disease in Russia and the CIS countries, with up to 1 million new cases and 100,000 deaths each year.

Solagran expects demand for Ropren to treat liver disease alone will reach 320,000 courses in 2010 and exceed 1 million courses per year by 2012.

Initially, the market is expected to be supply constrained, with Solagran only having capacity to meet the demand expected from hospitals and pharmacies in the cities of Moscow and St Pe! tersburg.

The next step for Solagran is to obtain a manufacturing licence which will apply throughout Russia. This process involves obtaining approval firstly at local level, followed by state and finally federal level approval. It is a procedure that usually takes 2-3 months.

Solagran is already well advanced with the expansion of the SibEX plant in Tomsk into a facility capable of producing 20kg of Bioeffective® R per month by November 2007. This will translate into 60,000 courses of Ropren per year. Planning is also progressing in relation to the development of a new plant on SibEX land adjacent to the existing facility that will be capable of producing 100-200kg per month or 300-600,000 courses per year.

At least three additional production facilities are now planned for Russia to produce Bioeffective® A, Bioeffective® V and Bioeffective® R.

Beyond that, Solagran is looking to establish sites in Finland and in Nort! h America (potentially in either British Columbia or the Pacif! ic North west).
An Executive Director has been appointed with primary responsibility for overseeing Solagran's global manufacturing capability.

Solagran's current strategy involves firstly building a strong market position in Russia with Ropren and Bioeffective® A, and then using Russia as a base to take Ropren and other Bioeffectives® to the world.

Chronic liver disease is a significant global problem. In the US, there are some 200,000 new cases, 300,000 hospitalisations and 30,000 deaths each year. Nevertheless, Solagran expects Ropren's very real potential to prevent and treat neurodegenerative disorders (including Alzheimer's and Parkinson's diseases), together with its ability to normalise cholesterol levels, will have a particularly significant impact in that country over time.

While the intention is to obtain registration for Ropren in the European Union prior to pursuing FDA registration in the US, there is a possibility that b! oth could be done in parallel. Enquiries have already been received from a considerable number of individual patients and their families in Europe and the US in relation to the availability of Ropren to treat both liver disease and neurodegenerative disorders.

At the same time, trials in St Petersburg are progressing well with both the injectable and liposomal forms of Bioeffective® R, as well as with Bioeffectives® A, B and N.

Solagran's Directors consider the registration of Bioeffective® R and Ropren to be by far the most significant milestone achieved by Solagran since it listed in 2003. Achieving full registration for a new and multi-faceted pharmaceutical substance of natural origin in less than four years is truly outstanding - particularly given the amount of change that was occurring within the Russian Ministry of Health during the time that Solagran's application was being processed. Normally, the approval process would take at least tw! ice as long.

Shortcutting this process was only ! possible due to the outstanding efficacy and safety of Ropren, the stature and reputation of Solagran's Executive Chairman Dr Vagif Soultanov within the Russian medical research community, the professionalism and dedication shown by Solagran's project team in Russia led by Professor Victor Roshchin.

Registration opens the door for Solagran to begin to activate its global development strategy. When executed successfully, that strategy has the potential to create a whole new direction in medicine involving the use of highly effective but low side-effect natural Bioeffectives®.

About Solagran Limited

Solagran is a biotechnology company with a portfolio of higly effective, low side effect, natural pharmaceuticals that it obtains from gree tree foliage. Its patented technology! enables the extraction of the live elements of trees in a way that both preserves and amplifies their biological activity.

http://www.solagran.com
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.